Artios

To add a bio or update company history, please click update information.

News from Artios

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

18 Nov 2025

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

Artios Pharma develops cancer treatments that target DNA damage response pathways, focusing on patient groups with limited existing treatment options.

Artios

Life Sciences
Cambridge, United Kingdom
£90m
artios.com
Update Information

More venture news

Lightcast
15 Apr 2026
Lightcast lands £20m in funding led by ARCH Venture Partners to advance single-cell analysis platform
EquityLife Sciences
Helical
14 Apr 2026
Helical raises a £7.5m seed round led by redalpine to build virtual labs for pharma research
SeedLife Sciences
Semarion
31 Mar 2026
Semarion secures £2.9m in funding led by Parkwalk to accelerate cell-based drug discovery
EquityLife Sciences

Artios

News from Artios

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

More venture news

Lightcast lands £20m in funding led by ARCH Venture Partners to advance single-cell analysis platform

Helical raises a £7.5m seed round led by redalpine to build virtual labs for pharma research

Semarion secures £2.9m in funding led by Parkwalk to accelerate cell-based drug discovery